Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
4.645
-0.005 (-0.11%)
Sep 18, 2026, 10:02 AM EDT - Market open
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $5.86M in the quarter ending June 30, 2026, a decrease of -53.85%. This brings the company's revenue in the last twelve months to $30.32M, up 106.21% year-over-year. In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth.
Revenue (ttm)
$30.32M
Revenue Growth
+106.21%
P/S Ratio
2.63
Revenue / Employee
$398,961
Employees
76
Market Cap
79.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| Pelthos Therapeutics | 43.30M |
| BioStem Technologies | 34.59M |
| Connect Biopharma Holdings | 2.95M |
| iBio, Inc. | 100.00K |
| NeOnc Technologies Holdings | 39.99K |
VRCA News
- 3 days ago - Verrica Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 days ago - Verrica Pharmaceuticals Slides: Corporate presentation - Filings
- 8 days ago - Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - GlobeNewsWire
- 10 days ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 22 days ago - Lake Street starts Verrica Pharmaceuticals with a Buy - TheFly
- 22 days ago - Verrica Pharmaceuticals initiated with a Buy at Lake Street - TheFly
- 22 days ago - Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals CEO buys $125.8K in common stock - TheFly